EA009807B1 - Антитело против igf-i-рецептора - Google Patents

Антитело против igf-i-рецептора Download PDF

Info

Publication number
EA009807B1
EA009807B1 EA200600931A EA200600931A EA009807B1 EA 009807 B1 EA009807 B1 EA 009807B1 EA 200600931 A EA200600931 A EA 200600931A EA 200600931 A EA200600931 A EA 200600931A EA 009807 B1 EA009807 B1 EA 009807B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
therapeutic agent
receptor
cancer
antibodies
Prior art date
Application number
EA200600931A
Other languages
English (en)
Russian (ru)
Other versions
EA200600931A1 (ru
Inventor
Раджиева Сингх
Дэниэл Дж. Таварес
Ненси И. Дагдайгиен
Original Assignee
Иммьюноджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Иммьюноджен, Инк. filed Critical Иммьюноджен, Инк.
Publication of EA200600931A1 publication Critical patent/EA200600931A1/ru
Publication of EA009807B1 publication Critical patent/EA009807B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA200600931A 2003-12-08 2004-12-07 Антитело против igf-i-рецептора EA009807B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (2)

Publication Number Publication Date
EA200600931A1 EA200600931A1 (ru) 2006-10-27
EA009807B1 true EA009807B1 (ru) 2008-04-28

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600931A EA009807B1 (ru) 2003-12-08 2004-12-07 Антитело против igf-i-рецептора

Country Status (13)

Country Link
EP (1) EP1692176A4 (de)
JP (1) JP2008502589A (de)
KR (1) KR20070001883A (de)
CN (1) CN1886424A (de)
AU (1) AU2004303792A1 (de)
BR (1) BRPI0417406A (de)
CA (1) CA2548065A1 (de)
CR (1) CR8426A (de)
EA (1) EA009807B1 (de)
EC (1) ECSP066595A (de)
IL (1) IL174770A0 (de)
MX (1) MXPA06005540A (de)
NO (1) NO20063155L (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226961B2 (en) 2009-12-21 2016-01-05 Genentech, Inc. Antibody formulation

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034780A2 (en) * 1998-12-04 2000-06-15 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
US20030235582A1 (en) * 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399483B1 (de) * 2001-01-05 2010-04-14 Pfizer Inc. Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034780A2 (en) * 1998-12-04 2000-06-15 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
US20030235582A1 (en) * 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Maloney E.K. et al. An Anti-Insulin-like Growth Fcator Receptor Antibody that is a Potent Inhibitor of Cancer Cell Proliferation, 15 August 2003, Vol. 63, pages 5073-5083, see entire document *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226961B2 (en) 2009-12-21 2016-01-05 Genentech, Inc. Antibody formulation

Also Published As

Publication number Publication date
AU2004303792A1 (en) 2005-07-07
CA2548065A1 (en) 2005-07-07
KR20070001883A (ko) 2007-01-04
ECSP066595A (es) 2006-10-17
CN1886424A (zh) 2006-12-27
NO20063155L (no) 2006-08-11
EP1692176A1 (de) 2006-08-23
IL174770A0 (en) 2006-08-20
EP1692176A4 (de) 2008-11-12
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
JP2008502589A (ja) 2008-01-31
CR8426A (es) 2007-12-04
BRPI0417406A (pt) 2007-04-03

Similar Documents

Publication Publication Date Title
AU2003241580B2 (en) Anti-IGF-I receptor antibody
US8034904B2 (en) Anti-IGF-I receptor antibody
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
CN102958534B (zh) Notch1结合剂及其使用方法
EA014298B1 (ru) Анти-il-17-антитела
BR112021012608A2 (pt) Porção de ligação que se liga especificamente à claudina18.2, receptor de antígeno quimérico, ácido nucleico, célula imune manipulada, composição farmacêutica, e, método de tratamento de um tumor ou câncer que expressa claudina18.2
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
EA009807B1 (ru) Антитело против igf-i-рецептора
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
CN116284427A (zh) 抗muc17/cd3双特异性抗体、其制备方法及用途
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
KR20050021001A (ko) 인간 인슐린-유사 성장인자-i 수용체 항체

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU